Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.38 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7686070 | 0.91 | MAPK1 (0.43) | MAPK1CYP2A6CYP3A4CYP2B6CYP2D6 | |
| SCHEMBL1133233 | 0.86 | CYP2A6 (0.47) | MAPK1CYP2A6CYP3A4CYP2B6CYP2D6 | |
| SCHEMBL2323022 | 0.84 | HRH1 (0.48) | MAPK1CYP2A6CYP3A4CYP2B6CYP2D6 | |
| SCHEMBL16458131 | 0.83 | MAPK1 (0.40) | MAPK1CYP2A6CYP3A4CYP2B6CYP2D6 | |
| SCHEMBL5673498 | 0.83 | SMN1; SMN2 (0.36) | MAPK1PDGFRBALDH1A1PIM1 | |
| SCHEMBL5025500 | 0.82 | MAPK1 (0.43) | MAPK1CYP2A6CYP3A4CYP2B6CYP2D6 | |
| SCHEMBL6570950 | 0.82 | MAPK1 (0.39) | MAPK1CYP2A6CYP3A4CYP2B6CYP2D6 | |
| SCHEMBL5677776 | 0.82 | MAPK1 (0.34) | MAPK1CYP2A6CYP3A4CYP2B6CYP2D6 | |
| SCHEMBL4861987 | 0.82 | GSK3B (0.43) | MAPK1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL7067440 | 0.82 | MAPK1 (0.41) | MAPK1CYP2A6CYP3A4CYP2B6CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124744-B2 | Macrolide derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | claimed |
| EP-2077271-A1 | MACROLIDE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-07-08 | — | — | EP | claimed |
| US-20090076253-A1 | MACROLIDE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2009-03-19 | — | — | US | claimed |
| EP-1171447-A2 | KETOLIDE ANTIBACTERIALS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-01-16 | — | — | EP | claimed |
| WO-2000062783-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-10-26 | — | — | WO | claimed |
| EP-2613630-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Cempra Pharmaceuticals, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| WO-2012034058-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
| US-8124744-B2 | Macrolide derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-02-28 | — | — | US | disclosed |
| US-8076301-B2 | 10-substituted macrolide antibiotics | C10 PHARMA AS (NO) | 2011-12-13 | — | — | US | disclosed |
| EP-2371833-A2 | 10-substituted macrolide antibiotics | C10 Pharma AS (NO) | 2011-10-05 | — | — | EP | disclosed |
| EP-2354147-A2 | 10-substituted macrolide antibiotics | C10 Pharma AS (NO) | 2011-08-10 | — | — | EP | disclosed |
| US-20100137234-A1 | 10-SUBSTITUTED MACROLIDE ANTIBIOTICS | C10 PHARMA AS (NO) | 2010-06-03 | — | — | US | disclosed |
| US-6756359-B2 | ADMINISTERING A 14 MEMBERED MACROLIDE AND KETOLIDE ANTIBIOTICS CONTAINING C12 MODIFICATIONS TO A PATIENT SUFFERING FROM BACTERIAL INFECTIONS | CHIRON CORPORATION | 2004-06-29 | — | — | US | disclosed |
| EP-1404693-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2004-04-07 | — | — | EP | disclosed |
| EP-1345953-A2 | KETOLIDE ANTIBACTERIALS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | CHU DANIEL (US) | 2003-07-03 | — | — | US | disclosed |
| WO-2003004509-A2 | C12 MODIFIED ERYTHROMYCIN MACROLIDES AND KETOLIDES HAVING ANTIBACTERIAL ACTIVITY | CHIRON CORPORATION (US) | 2003-01-16 | — | — | WO | disclosed |
| WO-2002032918-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-04-25 | — | — | WO | disclosed |
| EP-1171447-A2 | KETOLIDE ANTIBACTERIALS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-01-16 | — | — | EP | disclosed |
| WO-2000062783-A2 | KETOLIDE ANTIBACTERIALS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125266-A1 | C12 Modified erythromycin macrolides and ketolides having antibacterial activity | MRPL21, CYP51A1, CEL | MAPK1 1687/4885CYP2A6 68/4885CYP3A4 120/4885 |
| US-20090076253-A1 | MACROLIDE DERIVATIVES | MMP9, MMP2, MMP11 | MAPK1 1358/4885CYP2A6 1058/4885CYP3A4 1429/4885 |
| US-20100137234-A1 | 10-SUBSTITUTED MACROLIDE ANTIBIOTICS | RPLP0, RPS10, MRPL21 | MAPK1 4786/4885CYP2A6 1078/4885CYP3A4 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.